GI CANCERS | Clinical

TOPAZ-1 Data Support New Frontline Option in Patients With BTC

January 30, 2023

During a Targeted Oncology case-based roundtable event, Nilofer S. Azad, MD, discussed the data supporting the previous standard of care and the new frontline regimen of gemcitabine, cisplatin, and durvalumab for patients with biliary tract cancers.

Futibatinib Sustains Benefit in Advanced/Metastatic FGFR2+ iCCA

January 25, 2023

Phase 2 FOENIX-CCA2 study results further confirm the safety and efficacy of futibatinib for the treatment of previously treated patients with advanced/metastatic intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

Adding Veliparib or Pembrolizumab to Neoadjuvant Chemoradiation Not Beneficial for Locally Advanced Rectal Cancer

January 21, 2023

NRG-GI002 helps to provide further total neoadjuvant therapy outcome data from multi-institutional national clinical trials that can benchmark and be used for future locally advanced rectal cancer outcomes, according to Thomas J. George, MD, FACP.